In the present study, we investigated the synergistic effect of using an anti-PD-1 antibody to enhance the anti-tumor immunity induced by the intratumoral injection of rAd-p53 in experimental syngeneic mouse tumor models of kidney, bladder and prostate cancers in vitro and in vivo. This evidence concerns the gene TP53 and prostate carcinoma.